<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088461</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-35-16</org_study_id>
    <nct_id>NCT04088461</nct_id>
  </id_info>
  <brief_title>Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine</brief_title>
  <acronym>RESCATHEME</acronym>
  <official_title>Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Guanajuato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Regional de Alta Especialidad del Bajio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Guanajuato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this protocol is to evaluate the effect of addhing linagliptin to patients with
      prediabetes who do not reverse to normoglycemia after 12 months of treatment with metformin
      alone. The duration of the study will be 6 months, and it is primarily a efficacy study. Main
      outcomes will be glucose levels during OGTT, insulin secretion and pancreatic beta cell
      function measured by the disposition index derived from the OGTT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization and masking. Patients will be randomly assigned in a 1:1 ratio to receive
      linagliptin/metformin 2.5/850mg every 12 h + lifestyle modification program, or metformin
      850mg every 12 h + lifestyle modification program during 6 months. Randomization will be
      performed using an electronic random numbers table by a Nutritionist not involved in the
      study. Participants and investigators involved in the patients follow-up and outcome
      measurements will be masked to treatment allocation during the entire study.

      Patients will have a follow-up visit every month. Every appointment is about 30-45 minutes;
      medications tolerance and side effects will be recorded in every patients´ visit. Nutritional
      and physical activity assessment according to the patient´s weight will be performed by a
      Nutritionist every month. Monthly adherence to medications will be evaluated by pill
      counting; nutritional adherence and energy intake will be evaluated at 6 months by a food
      frequency questionnaire, and physical activity at 0 and 6 months. At basal and at 6 months
      patients will have an OGTT. Primary objective is to evaluate at 6 months glucose profile
      during OGTT, insulin secretion and pancreatic β-cell function by the OGTT DI, and regression
      to normoglycemia; T2D will be diagnosed and confirmed by at least two consecutive
      measurements of the same criteria: glycated haemoglobin ≥ 6.5 %, fasting glucose ≥ 126mg/dl,
      or 2 h glucose ≥ 200 mg/dl.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose levels during OGTT</measure>
    <time_frame>6 months</time_frame>
    <description>Glucose levels during OGTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic beta cell function</measure>
    <time_frame>6 months</time_frame>
    <description>Pancreatic beta cell function measured with the disposition index during OGTT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Prediabetic State</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Linagliptin + Metformin and lifestyle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin / Metformin Oral Tablet</intervention_name>
    <description>Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program</description>
    <arm_group_label>Linagliptin + Metformin and lifestyle</arm_group_label>
    <other_name>Combined treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg twice daily plus lifestyle modifications program</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with impaired glucose tolerance (2 h glucose between 140 - 199 mg / dL) that
             after 1 year of treatment with metformin at a dose of 1700 mg daily + lifestyle
             modifications don't achieve normoglycemia.

          -  Patients who accept to participate in the study and sign informed consent.

        Exclusion Criteria:

          -  Patients with type 2 Diabetes diagnosted previuosly or detected during the OGTT

          -  Serum creatinine &gt; 1.6 mg/dL

          -  Hypertriglyceridemia very high (&gt;500 mg/dL)

          -  Pregnancy

          -  Systolic blood pressure &gt; 180 mmHg or Diastolic blood pressure &gt;105 mmHg (patients
             could be re-screened after blood pressure control)

          -  Excessive alcohol intake, acute or chronic

          -  Medications or medical conditions that affect glucose homeostasis (thiazides, beta
             blockers, glucocorticoids for systemic use, weight-reducing drugs or anorexigenics,
             Cushing's syndrom, Thyrotoxicosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Guardado Mendoza, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Guanajuato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de Guanajuato</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Guanajuato</investigator_affiliation>
    <investigator_full_name>Rodolfo Guardado Mendoza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>hyperglucemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04088461/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

